Loading...
Market
How many participants will be enrolled in the Phase 3 trial for DengiAll vaccine by December 31, 2024?
2
Resolution / Starting Odds
Less than 5,000 • 25%
5,000 to 10,000 • 25%
10,001 to 20,000 • 25%
More than 20,000 • 25%
Official announcement from ICMR or Panacea Biotec
Story
ICMR and Panacea Biotec Start Phase 3 Trial for DengiAll, India's First Indigenous Dengue Vaccine
Aug 14, 2024, 12:15 PM
The Indian Council of Medical Research (ICMR) and pharmaceutical company Panacea Biotec have initiated the first-ever Phase 3 clinical trial for a dengue vaccine in India. The indigenous vaccine, named DengiAll, marks a significant advancement in the fight against dengue. The trial began with the administration of the first dose in Rohtak, Haryana, ahead of India's Independence Day 2024. This development comes as dengue cases remain a concern in India, with 289,235 cases and 485 deaths reported in 2023, according to the National Centre for Vector Borne Diseases Control Programme.
View original story
Similar markets
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
0-1000 • 25%
1001-2000 • 25%
2001-3000 • 25%
3001+ • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
0-5 sites • 25%
6-10 sites • 25%
11-15 sites • 25%
16-20 sites • 25%
Less than 50 • 25%
50 to 100 • 25%
101 to 200 • 25%
More than 200 • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
Less than 50 • 25%
50-100 • 25%
101-200 • 25%
More than 200 • 25%
Dose escalation • 25%
Safety assessment • 25%
Efficacy assessment • 25%
Trial termination • 25%
0-10 • 25%
11-20 • 25%
21-30 • 25%
31 or more • 25%